Immunovant Inc (IMVT)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue 0 160,000 0 0
Cost of Revenue 107,000 80,000 0 0
Gross Profit -107,000 80,000 0 0
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 26,024,000 20,254,000 19,782,000 18,471,000
Operating Expenses 127,224,000 113,906,000 114,302,000 115,743,000
Operating Income -127,224,000 324,326,000 -114,302,000 -115,743,000
Interest Expense 0 0 0 0
Income Before Tax -119,700,000 -105,865,000 -110,970,000 -109,041,000
Income Tax Expense 913,000 584,000 152,000 78,000
Net Income -120,613,000 -106,449,000 -111,122,000 -109,119,000
Per Share
EPS -0.71 -0.63 -0.76 -0.74
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Revenue 0 0 0 0 0
Cost of Revenue 377,000 231,000 1,324,000 1,232,000 0
Gross Profit -377,000 -231,000 -1,324,000 -1,232,000 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 77,235,000 57,281,000 48,019,000 54,225,000 39,513,000
Operating Expenses 438,152,000 282,709,000 208,276,000 156,033,000 108,117,000
Operating Income -438,152,000 -282,709,000 -198,469,000 -156,159,000 -108,117,000
Interest Expense 0 0 12,482,000 655,000 0
Income Before Tax -412,949,000 -258,769,000 -210,951,000 -156,814,000 -107,789,000
Income Tax Expense 891,000 567,000 9,000 -84,000 -358,000
Net Income -413,840,000 -259,336,000 -210,960,000 -156,730,000 -107,431,000
Per Share
EPS -2.73 -1.88 -1.71 -1.43 -1.22
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Assets
Cash and Cash Equivalents 713,971,000 635,365,000 376,532,000 493,817,000
Short Term Investments 0 0 0 0
Net Receivables 2,511,000 5,503,000 885,000 12,861,000
Inventory 0 0 0 0
Total Current Assets 767,662,000 665,770,000 404,333,000 512,931,000
Property Plant Equipment 942,000 595,000 1,505,000 2,633,000
Goodwill and Intangibles 0 0 0 0
Total Assets 776,222,000 666,365,000 405,838,000 515,564,000
Liabilities
Account Payables 17,656,000 7,155,000 1,353,000 18,629,000
Short Term Debt 98,000 138,000 1,173,000 1,145,000
Total Current Liabilities 68,775,000 48,608,000 43,297,000 44,520,000
Long Term Debt 0 0 47,000 1,219,000
Total Liabilities 68,775,000 48,608,000 43,344,000 45,739,000
Shareholders Equity
Retained Earnings -1,239,523,000 -825,683,000 -566,347,000 -355,387,000
Total Shareholders Equity 707,447,000 617,757,000 362,494,000 469,825,000
Balance Sheet (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Assets
Cash and Cash Equivalents 713,971,000 635,365,000 376,532,000 493,817,000 400,146,000
Short Term Investments 0 0 0 0 0
Net Receivables 2,511,000 5,503,000 885,000 12,861,000 548,000
Inventory 0 0 0 0 0
Total Current Assets 767,662,000 665,770,000 404,333,000 512,931,000 409,006,000
Property Plant Equipment 942,000 595,000 1,505,000 2,633,000 3,483,000
Goodwill and Intangibles 0 0 0 0 0
Total Assets 776,222,000 666,365,000 405,838,000 515,564,000 412,489,000
Liabilities
Account Payables 17,656,000 7,155,000 1,353,000 18,629,000 2,432,000
Short Term Debt 98,000 138,000 1,173,000 1,145,000 1,179,000
Total Current Liabilities 68,775,000 48,608,000 43,297,000 44,520,000 18,771,000
Long Term Debt 0 0 47,000 1,219,000 2,238,000
Total Liabilities 68,775,000 48,608,000 43,344,000 45,739,000 21,009,000
Shareholders Equity
Retained Earnings -1,239,523,000 -825,683,000 -566,347,000 -355,387,000 -198,657,000
Total Shareholders Equity 707,447,000 617,757,000 362,494,000 469,825,000 391,480,000
Cash Flow Statement (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Activities
Net Income -413,840,000 -259,336,000 -210,960,000 -156,730,000
Depreciation & Amortization 377,000 231,000 193,000 126,000
Stock Based Compensation 49,487,000 41,116,000 32,296,000 34,244,000
Change in Working Capital -12,031,000 2,632,000 -10,853,000 15,142,000
Operating Cash Flow -375,874,000 -214,227,000 -188,193,000 -106,112,000
Investing Activities
Capital Expenditure -759,000 -360,000 -197,000 -254,000
Investments -759,000 -360,000 -197,000 -254,000
Investing Cash Flow -759,000 -360,000 -197,000 -254,000
Financing Activities
Debt Repayment 0 0 0 0
Common Stock Issued/Repurchased 454,492,000 472,745,000 70,500,000 129,000
Dividends Paid 0 0 0 0
Financing Cash Flow 454,492,000 472,427,000 70,885,000 200,129,000
Summary
Free Cash Flow -376,633,000 -214,587,000 -188,390,000 -106,366,000
Net Change in Cash 78,606,000 258,833,000 -117,285,000 93,671,000
Cash Flow Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Operating Activities
Net Income -413,840,000 -259,336,000 -210,960,000 -156,730,000 -107,431,000
Depreciation & Amortization 377,000 231,000 193,000 126,000 65,000
Stock Based Compensation 49,487,000 41,116,000 32,296,000 34,244,000 18,822,000
Change in Working Capital -12,031,000 2,632,000 -10,853,000 15,142,000 4,566,000
Operating Cash Flow -375,874,000 -214,227,000 -188,193,000 -106,112,000 -83,327,000
Investing Activities
Capital Expenditure -759,000 -360,000 -197,000 -254,000 -210,000
Investments -759,000 -360,000 -197,000 -254,000 -210,000
Investing Cash Flow -759,000 -360,000 -197,000 -254,000 -210,000
Financing Activities
Debt Repayment 0 0 0 0 -3,190,000
Common Stock Issued/Repurchased 454,492,000 472,745,000 70,500,000 129,000 319,783,000
Dividends Paid 0 0 0 0 0
Financing Cash Flow 454,492,000 472,427,000 70,885,000 200,129,000 383,112,000
Summary
Free Cash Flow -376,633,000 -214,587,000 -188,390,000 -106,366,000 -83,537,000
Net Change in Cash 78,606,000 258,833,000 -117,285,000 93,671,000 299,575,000